Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results and business update announced for quarter ended March 31, 2026.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results and business update announced for quarter ended March 31, 2026
- Financial position reported as of March 31, 2026
- Full operating results and management commentary contained in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.